Last10K.com

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 8-K Material Event for the period ending Friday, April 14, 2023

Aclaris Therapeutics, Inc.

HISTORY TOOLS
CIK: 1557746 Ticker: ACRS

View differences made from one to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information
N-2

Material Contracts, Statements, Certifications & more

Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: ACRS
CIK: 1557746
Form Type: 8-K Corporate News
Accession Number: 0001558370-23-005917
Submitted to the SEC: Fri Apr 14 2023 7:11:39 AM EST
Accepted by the SEC: Fri Apr 14 2023
Period: Friday, April 14, 2023
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-23-005917.htm